Relapsed and Refractory POMES Syndrome
1 clinical trials · Condition
◉ Watch Relapsed and Refractory POMES Syndrome
| Record | Firm | Date |
|---|---|---|
| Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES (NCT03879382) | Hrain Biotechnology Co., Ltd. | 2019-02-27 |
Track Relapsed and Refractory POMES Syndrome automatically
Every clearance here is in the API, with alerts when new ones post.